E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
The study population includes postmenopausal patients with advanced (locally recurrent, inoperable and/or metastatic), HR+, HER2- breast cancer. For peri-/premenopausal patients, endocrine therapy has to be combines with a luteinizing hormone-releasinghormone (LRHR) agonist. |
|
E.1.1.1 | Medical condition in easily understood language |
The study includes peri-/premenopausal and postmenopausal women with advances hormone receptor postive, HER2- breat cancer |
Peri-/prämenopausale und postmenopausale Patientinnen mit fortgeschrittener, hormonrezeptor positiver, HER2- negativer Brustkrebsekrankung )können eingeschlossen werden. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10072737 |
E.1.2 | Term | Advanced breast cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10027475 |
E.1.2 | Term | Metastatic breast cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 23.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10070575 |
E.1.2 | Term | Estrogen receptor positive breast cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate the efficacy of palbociclib in addition to an aromatase inhibitor or fulvestrant after prior endocrine therapy in pre-/perimenopausal and postmenopausal women with HR+/HER2- advanced breast cancer (locally advanced, inoperable or metastatic) as first or later-line of treatment. |
|
E.2.2 | Secondary objectives of the trial |
-To assess safety and tolerability -To assess efficacy -To assess treatment adherence -To assess health-related quality of life (QoL), fatigue, and anxiety and depression -To compare quality of life with real-life patients receiving first-line chemotherapy in the non-interventional MaLife study -To physician’s assessment of patient’s overall health status and change in health status -To explore whether organ-specific symptoms can serve as indicators for progressive disease -To establish a decentral, virtual biobank for the future collection and central analyses of predictive biomarkers of the CDK4/6 pathway
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Patients with proven diagnosis of advanced adenocarcinoma of the breast (locally advanced, inoperable or metastatic disease). - Patients with hormone-receptor-positive (HR+) disease, defined as ER+ and/or PgR+ - Patients with human-epidermal-growth-factor-receptor-2-negative (HER2-) disease - Pre-/perimenopausal women receiving concomitant therapy with an luteinizing hormone-releasing hormone (LHRH) agonist or postmenopausal status - Patients scheduled for palliative treatment with the combination of palbociclib and letrozole for first- or later-line, anastrozole for first-line, exemestane for first-line, or fulvestrant for first-or later-line after prior endocrine failure. - Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-2
|
|
E.4 | Principal exclusion criteria |
- Patient has received prior treatment with any CDK inhibitor - Prior adjuvant therapy with the respective endocrine combination partner if last intake <12 months prior to entering the study - Prior palliative therapy with the respective endocrine combination partner - More than one palliative chemotherapy for patients in treatment group 5 (second or later line, Palbociclib and Letrozole) and group 6 (Second or leter line, Palbociclib and Fulvestrant after prior endocrine therapy) - Patient has known, not-irradiated CNS metastases |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint of this study is to determine the Clinical Benefit Response (CBR) defined as proportion of patients with best overall response CBR is defined as complete response (CR), partial response (PR), or stable disease (SD) according to RECIST 1.1
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At 24 weeks after start of treatment with palbociclib and the respective combination partner. |
|
E.5.2 | Secondary end point(s) |
To assess safety and tolerability - Adverse Events as characterized by type, frequency, severity (as graded by National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] v.4.03), and seriousness until PD (or start of next anti-cancer therapy, whatever comes first) - Any laboratory abnormalities - Frequency and duration of hospitalizations To assess efficacy - CBR ≥24 weeks - Progression free survival (PFS) - Overall survival (OS) - CBR at 48 weeks of treatment - PFS rate after 48 weeks (all patients) and after 2 years of treatment (first-line patients only) - OS rate after 48 weeks (all patients), thereafter yearly until EOS (first-line patients only)ly) To assess treatment adherence - Time on treatment - Reasons for discontinuation of treatment - Dose adjustments (frequency, reason) - Patient diary until EOT To assess Health-related quality of life (QoL), fatigue, and anxiety and depression - Health-related QoL will be assessed with the FACT-B (Functional Assessment of Cancer Therapy-Breast) questionnaire every 12 weeks until PD (or start of next anti-cancer therapy, whatever comes first) - Fatigue will be assessed with the BFI (Brief Fatigue Inventory) questionnaire every 12 weeks until PD (or start of next anti-cancer therapy, whatever comes first) - Depression and anxiety be assessed with the HADS-D (Hospital Anxiety and Depression Scale) questionnaire every 12 weeks until PD (or start of next anti-cancer therapy, whatever comes first) To assess Physician’s assessment of patient’s overall health status and change in health status compared to previous visit - Assessed with 2 item questionnaire each cycle/at scheduled patient visit until progression of disease or start of next anti-cancer therapy whatever comes first.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Please see above Either at 24 weeks, at 48 weeks, after 2 years or at time point of progressive disease or start of next anti cancer therapy |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 80 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 85 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the entire study is defined as LPLV. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 6 |
E.8.9.1 | In the Member State concerned months | 3 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 6 |
E.8.9.2 | In all countries concerned by the trial months | 3 |
E.8.9.2 | In all countries concerned by the trial days | 0 |